Navigation Links
Non-dopaminergic drug preladenant reduces motor fluctuations in patients with Parkinson's disease

Tampa, FL (Feb. 10, 2011) -- Preladenant, a non-dopaminergic medication, reduces off time in patients with Parkinson's disease receiving standard dopamine therapy, an international study led by the University of South Florida found.

Results of the double-blind, randomized clinical trial are reported online today in the journal Lancet Neurology. The findings suggest that preladenant may offer a new supplemental treatment for Parkinson's disease without some of the complications of levodopa and other standard dopamine treatments.

"The goal of treatment is to provide the best possible function and quality of life to patients over time," said lead author Dr. Robert A. Hauser, director of the Parkinson's Disease and Movement Disorders Center at USF. "After a few years, many patients find that their traditional Parkinson's disease medications wear off after a few hours leading to a re-emergence of symptoms. In this study, preladenant was shown to reduce off time, thereby affording patients more time through the day with better function."

Dr. Hauser and colleagues evaluated the safety and effectiveness of a range of doses of preladenant in 253 patients experiencing "wearing off" symptoms from their levodopa therapy. The patients were also receiving other available anti-parkinsonian drugs, such as dopamine agonists and/or entacapone.

The 12-week study found that the addition of 5 and 10 mg of preladenant twice daily significantly reduced "off time" -- the re-emergence of troublesome motor symptoms such as slowness, stiffness, tremors, and immobility when compared to patients receiving similar doses of placebo. Futhermore, preladenant significantly increased "on time" the period during which patients' Parkinson's symptoms were adequately controlled --.without significantly worsening dyskinesia (involuntary twisting, turning movements). The doses were well tolerated, and the incidence of treatment-related adverse effects was similar for patients receiving preladenant and placebo.

In Parkinson's disease, the brain's dopamine-producing cells falter and die, leading to movement-related or motor symptoms such as tremors, stiffness, slowness, and balance problems.

Levodopa, a compound converted into dopamine in the brain, is still the gold standard therapy for Parkinson's, but as the disease advances this standard drug works for increasingly shorter time periods. As a result, patients begin to experience impaired movement before their next scheduled dose of medication. The re-emergence of symptoms accompanying this "off-time" can make it difficult for patients to perform even the most basic functions, such as walking and dressing. In addition, over time patients tend to develop a sensitivity to levodopa therapy during "on-time" resulting in involuntary twisting, turning movements known as dyskinesia.

Currently available drugs widely used to treat Parkinson's disease correct for the loss of the neurotransmitter dopamine either by boosting available dopamine in the brain or directly stimulating dopamine receptors. New ways to treat the disease that better address motor fluctuations without adverse side effects continue to be sought. Preladenant is a non-dopaminergic medication that targets adenosine A2A receptors in the motor control areas of the brain. It may offer advantages over dopamine medications, possibly including fewer side effects.

The clinical trial was conducted at 44 sites in 15 countries. Preladenant is an investigational medicine and is not approved for use.


Contact: Anne DeLotto Baier
University of South Florida (USF Health)

Related medicine news :

1. Extra testosterone reduces your empathy
2. Surgery for obstructive sleep apnea reduces daytime drowsiness
3. Anti-estrogen medication reduces risk of dying from lung cancer
4. Drug reduces the increase in fear caused by previous traumatic experiences in mice
5. Loss of gene promotes brain-tumor development, reduces survival, study finds
6. Study shows that CPAP therapy reduces fatigue, increases energy in patients with sleep apnea
7. Low-dose aspirin reduces death rates from range of cancers by between 20 and 30 percent
8. Annual breast cancer screening beginning at age 40 reduces mastectomy risk
9. Regular exercise reduces large number of health risks including dementia and some cancers
10. Canola-type rapeseed oil reduces the level of fibrinogen, a cause of thrombosis and inflammation
11. National study shows CT screening of former, current smokers reduces lung cancer deaths
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... been recognized once again for its stellar workplace culture with the company’s Cincinnati ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business ...
(Date:11/25/2015)... ... 2015 , ... Ministers, senior government and UN agencies, representatives ... of Excellence, and public R&D institutions, civil societies and other partners gathered today ... African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug ... a new cutting edge recovery program that has been 50 years in the making. ... individuals with the purpose to free addicts from the symptoms and negative behaviors of ...
(Date:11/25/2015)... ... ... On November 23rd 2015 Cozy Products, a division of Bird-X Incorporated, ... explains what this means for business moving forward. , The Tri Lite heater business ... to sell personal heaters that reduce energy consumption, are economical and keep people warm ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... UTRECHT , Nederland, November 26, 2015 ... --> Een nieuwe aanpak combineert ... van gevorderde kanker. ... -->      (Photo: ... van het Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
Breaking Medicine Technology: